Beruflich Dokumente
Kultur Dokumente
2
Executive Summary
Inclusion Criteria
Previously healthy
Age 14 days
Born at 35 wks gestational age
Exclusion Criteria
Direct hyperbilirubinemia
Meets NICU Direct Admit Criteria
TSB > 5mg/dL above exchange
transfusion threshold
Signs of acute bilirubin
encephalopathy
Suspected sepsis or
ill-appearing
NICU
(Off Pathway)
PHASE I (E.D.)
Pathophysiology
Initial Assessment
!
Supplemental
IV Fluids NOT
routinely indicated
Admit on phototherapy
Discharge
Inpatient
Admission
ED Management
TSB rising or
meeting NICU
admission criteria
TSB stable or
falling and otherwise
clinically well
Inclusion Criteria
Previously healthy
Age 14 days
Born at 35 wks gestational age
Exclusion Criteria
Direct hyperbilirubinemia
Meets NICU Direct Admit Criteria
TSB > 5mg/dL above exchange
transfusion threshold
Signs of acute bilirubin
encephalopathy
Suspected sepsis or ill-appearing
Supplemental
IV Fluids NOT
routinely indicated
!
Rebound TSB
NOT routinely
indicated prior to
discharge
Inpatient Management
Initiate Hyperbilirubinemia (Neonatal) Admit Orders
If direct admit, obtain baseline total serum bilirubin (TSB)
Continue effective phototherapy until TSB at least 3 mg/dL below phototherapy threshold
feeding The infant should not be removed from bili lights for > 20 mins in any 3
Encourage feeding.
hour period. Use bottle if needed.
If patient unable to maintain normal temperature in an open crib, place in isolette per
Isolette
Isolette Use
Use Policy
Policy &
& Procedure
Procedure
Consider additional labs for patients meeting NICU consult criteria
Run maintenance IV fluids for patients within 2 mg/dL of exchange transfusion threshold or
with rapidly rising TSB. Stop IVF once TSB has fallen to at least 2 mg/dL below exchange
transfusion threshold and feeding well (e.g. at 72 hours of age, exchange transfusion threshold
24 and TSB less than 22)
No
No
Yes
Subsequent Labs
Subsequent Labs
Discharge
Return to ED Management
Return to ED Management
Go to Pathophysiology Pg 2
Return to ED Management
Return to Inpatient Management
Go to Pathophysiology Pg 3
Return to ED Management
Go to Pathophysiology Pg 4
Return to ED Management
Return to ED Management
Return to ED Management
Return to Inpatient Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Feeding
Encourage feeding. The infant should not be removed from bili lights for
> 20 mins in any 3 hour period. Use bottle while remaining under bili
lights if needed
Use maternal expressed breast milk for supplemental feeds, when
available
Lactation consultation if mom desires to breast feed
Rationale:
Formula feeds and breastfeeding are equally effective at reducing serum
bilirubin during phototherapy.
[LOE: moderate quality (NICE 2010)]
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Return to ED Management
Executive Summary
Executive Summary
Return to ED Management
Self-Assessment
Completion qualifies you for 1 hour of Category II CME credit. If you are taking this self-assessment as a
part of required departmental training at Seattle Childrens Hospital, you MUST logon to Learning Center.
1.
Which of the following patients would not be eligible for the neonatal jaundice pathway?
a. 5 day old term infant with a total serum bilirubin of 22.4, direct of 1.5
b. 3 day old ex-36 week SGA infant with a total serum bilirubin of 19.2, direct of 0.3
c. 6 day old lethargic ex-39 week infant with delayed capillary refill and total serum bilirubin of
21.1, direct of 0.1
d. 60 hour old ex-37 week infant with a total serum bilirubin of 21.9, Coombs+
2.
A 5 day old ex-39 week infant had TSB of 21.7 at PCP earlier today. Weight loss is ~11% from birth.
Infant is otherwise well. Moms milk has just come in. In the ED, in addition to a TSB, initial
laboratory screening would include:
a. Complete blood count
b. Direct antibody test (DAT)
c. Blood glucose level
d. Electrolytes
e. All of the above
3.
In the same patient (5 day old ex-39 week infant, TSB of 21.7 from PCP, ~11% weight loss from
birth, otherwise well, moms milk just come in), what would be appropriate to do in the ED while
awaiting initial laboratory results?
a. Keep the baby NPO
b. Administer a 20 mL/kg normal saline IV bolus
c. Consult the NICU
d. Start phototherapy
4.
True or False: Supplemental IV fluids are routinely indicated in the treatment of neonatal
hyperbilirubinemia?
5.
A 96 hour old ex-38 week infant presents to the ED with a total serum bilirubin of 21.9. He is
otherwise well. What is the most appropriate next step?
a. Keep the baby NPO
b. Start phototherapy and admit to the floor
c. Give a 20 mL/kg normal saline IV bolus
d. Consult the NICU
6.
A 48 hour old ex-37 week infant presents to the ED with a total serum bilirubin of 19.1. All of the
following would be appropriate except:
a. Bottle feed ad lib
b. Continue breast feeding up to 20 minutes every 2-3 hours
c. Give a 20 mL/kg normal saline IV bolus
d. Consult the NICU
e. Start phototherapy
7.
You are initiating phototherapy for a patient and measure irradiance of 23 W/cm2/nm. You
should:
a. Adjust the overhead light until the radiometer reading is less than 20 W/cm2/nm
b. Adjust the overhead light until the radiometer reading is at least 30 W/cm2/nm
c. Adjust the overhead light until the radiometer reading is at least 50 W/cm2/nm
d. Nothing
e. Remove the infant's diaper to expose more surface area then recheck the radiometer reading
8.
9.
A 4 day old ex-38 week infant born at home presents to the ED looking "yellow" for the last few
days. He is now refusing to latch with arching and extreme fussiness. Which next step is
associated with the best outcome?
a. Give a normal saline IV bolus as soon as possible in the ED
b. Obtain a total serum bilirubin immediately in the ED
c. Start phototherapy
d. Admit immediately to the NICU for rapid exchange transfusion
10.
You have treated a now 6 day old ex-term infant with 16 hours of phototherapy for breastfeeding
jaundice. TSB declined from peak of 21.2 to now 14.8. What is the best next step?
a. Stop phototherapy and check a TSB in 8 hours
b. Stop phototherapy and check a TSB in 12 hours
c. Continue phototherapy and check TSB q12 hours until < 12 mg/dL
d. Discharge home on home phototherapy
e. Discharge home
f. Discharge home with PCP follow up in 2-3 days
View Answers
Return to ED Management
Answer Key
1.
Answer: c.
Infants with systemic illness (e.g. sepsis) should be excluded from the pathway.
2.
Answer: c.
Breastfeeding jaundice; NICU consult criteria not met. Labs minimized to TSB and blood glucose.
3.
Answer: d.
Not close to exchange & TSB not rapidly rising. Outside TSB met threshold to initiate phototherapy.
4.
Answer: false.
Routine use of supplemental IV fluids is not indicated.
5.
Answer: b.
TSB is above phototherapy threshold, but not within 2 mg/dL of exchange.
6.
Answer: b.
Do not interrupt phototherapy when near exchange level.
7.
Answer: b.
The minimum recommended dose is 30 W/cm2/nm.
8.
Answer: c.
Frequent checks are indicated when near exchange.
9.
Answer: d.
Infants with signs of acute bilirubin encephalopathy should be admitted directly to NICU.
10.
Answer: e.
Rebound TSB not routinely necessary prior to discharge, F/U appt next day.
Return to ED Management
Evidence Ratings
We used the GRADE method of rating evidence quality. Evidence is first assessed as to
whether it is from randomized trial, or observational studies. The rating is then adjusted in
the following manner:
Quality ratings are downgraded if studies:
Have serious limitations
Have inconsistent results
If evidence does not directly address clinical questions
If estimates are imprecise OR
If it is felt that there is substantial publication bias
Quality ratings can be upgraded if it is felt that:
The effect size is large
If studies are designed in a way that confounding would likely underreport the magnitude
of the effect OR
If a dose-response gradient is evident
Quality of Evidence:
High quality
Moderate quality
Low quality
Very low quality
Expert Opinion (E)
Reference: Guyatt G et al. J Clin Epi 2011: 383-394
To Bibliography
Return to ED Management
Return to ED Management
Medical Disclaimer
Medicine is an ever-changing science. As new research and clinical experience
broaden our knowledge, changes in treatment and drug therapy are required.
The authors have checked with sources believed to be reliable in their efforts to
provide information that is complete and generally in accord with the standards
accepted at the time of publication.
However, in view of the possibility of human error or changes in medical sciences,
neither the authors nor Seattle Childrens Healthcare System nor any other party
who has been involved in the preparation or publication of this work warrants that
the information contained herein is in every respect accurate or complete, and
they are not responsible for any errors or omissions or for the results obtained
from the use of such information.
Readers should confirm the information contained herein with other sources and
are encouraged to consult with their health care provider before making any
health care decision.
Return to ED Management
Bibliography
Identification
52 records identified through
database searching
Screening
48 records after duplicates removed
48 records screened
21 records excluded
Elgibility
Included
6 studies included in pathway
Flow diagram adapted from Moher D et al. BMJ 2009;339:bmj.b2535
To Bibliography
Return to ED Management
Bibliography
American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the
newborn infant 35 or more weeks gestation. Pediatrics. 2004;114(1):297-316
American Academy of Pediatrics, Subcommittee on Hyperbilirubinemia. Phototherapy to prevent severe neonatal
hyperbilirubinemia in the newborn infant 35 or more weeks gestation. Pediatrics. 2011;128(4):e1046-e1052
Atkinson LR, et al. Phototherapy use in jaundiced newborns in a large managed care organization: do clinicians
adhere to the guideline? Pediatrics .2003;111:e555
Barak M, et al. When should phototherapy be stopped? A pilot study comparing two targets of serum bilirubin
concentration. Acta Paediatrica. 2009; 98:(2)277-281
Bhutani VK, et al. A systems approach for neonatal hyperbilirubinemia in term and near-term newborns. J Obstet
Gynecol Neonatal Nurs. 2006;35:444-455
Chavez GF, et al. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA. Jun 26
1991;265(24):3270-4
Eggert LD, et al. The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18hospital health system. Pediatrics. 2006;117:e855-e862
Harris M, et al. Developmental follow-up of breastfed term and near-term infants with marked hyperbilirubinemia.
Pediatrics. 2001;107:1075-1080
Kaplan M, et al. Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia.
Archives of Disease in Childhood. 2006; 91:(1)31-34
Maisels MJ, Kring E. Bilirubin rebound following intensive phototherapy. Arch Pediatr Adolesc Med. 2002;156(7):669
672
Maisels MJ, Kring EA. Length of stay, jaundice, and hospital readmission. Pediatrics. 1998;101:995-998
Murray NA, Roberts IA. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. Mar 2007;92(2):F83-8
National Institute for Health and Clinical Excellence. Neonatal jaundice. (Clinical guideline 98.) 2010.
www.nice.org.uk/CG98
Newman TB, et al. Frequency of neonatal bilirubin testing and hyperbilirubinemia in a large health maintenance
organization. Pediatrics. 1999;104:1198-1203
Spencer J. Common problems of breastfeeding and weaning. UpToDate. March 2012. http://uptodate.com
Tan KL. The nature of the dose-response relationship of phototherapy for neonatal hyperbilirubinemia. J Pediatr.
1977;90(3):448-452
Tan KL. The pattern of bilirubin response to phototherapy for neonatal hyperbilirubinemia. Pediatr Res. 1982;16(8):670674
Wagle S, Rosenkrantz T (ed.). Hemolytic Disease of Newborn. Medscape Reference. May 2011.
http://emedicine.medscape.com
Return to ED Management